PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) — Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services, and proprietary medical products, today announced its operating results for the three months ended March 31, 2026. “For the first quarter of 2026, the Company recorded total revenue of $19.4 million, a decrease of 0.5% when compared to the same quarter of the prior year, but an increase of 4.8% when excluding revenue of the healthcare IT service business we divested in November 2025,” commented Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Gross profit for the quarter was $11.6 million, up by 1.9% year over year, or by 5.8% without the healthcare IT service business; and net loss for the first three...

Building on 2025 Momentum as Operating Performance Improves and the Company Scales Its IP-Driven Strategy  Distribution Revenue Climbs 15% Compared to Prior Year Period as Streamers, Kartoon Channel! and Ameba Expand Engagement and Monetization Kartoon Channel Continues Strategic Expansion of Globally Recognized Entertainment Brands With Licensing Deal for Mattel’s Animated Series Masters of the Universe (2002) and American Girl (2016) Operating Costs Decline 20% as Loss From Operations Continues to Narrow Year-Over-Year Reflecting Continued Operating Discipline  Flagship Franchises, “Hundred Acre Wood” and “Stan Lee Universe”, Advance Toward Commercialization and Long-Term Monetization   BEVERLY HILLS, Calif., May 15, 2026 (GLOBE NEWSWIRE) — Kartoon Studios (NYSE American: TOON) today reported financial results for the...

Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases MELBOURNE, Australia, May 15, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30). Corporate and R&D Highlights Executes Service Agreement with FyoniBio GmbH to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study Management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development...

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026:Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026. The Company achieved a gross profit of approximately $76 thousand in the first quarter of 2026, compared with a gross profit of approximately $90 thousand in the first quarter of 2025. Operating expenses were approximately $2.17 million in the first quarter of 2026, compared with approximately $2.09 million in the...

Highlights Strategic Expansion into AI Continuity Infrastructure for Regulated Industries Conference Call to be Held Today at 11:00 am ET NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Data Storage Corporation (Nasdaq: DTST) (“DTST” and the “Company”), today provided a business update for the first quarter ended March 31, 2026, highlighting the Company’s strategic initiatives focused on emerging AI infrastructure opportunities and regulated enterprise continuity solutions. Business Highlights:Launching Sovereign AI Solutions (SaiS): Establishing a wholly owned subsidiary, Sovereign AI Solutions (“SaiS”), focused on developing a purpose-built AI Continuity Control Plane for regulated industries designed to support recovery, validation, and compliance for sovereign AI and AI Factory environments across sectors such as healthcare, financial...

NEW YORK and TOKYO, May 15, 2026 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), an IPO consulting services company based in Tokyo, reported financial results for the first quarter ended March 31, 2026. Recent Operational HighlightsAs of March 31, 2026, HeartCore was engaged with 16 Go IPO clients, including 6 clients currently in various stages of preparation for potential public registrations and U.S. exchange listings Regained Nasdaq $1.00 minimum bid price requirement Authorized $2.0 million share repurchase programManagement CommentaryHeartCore CEO Sumitaka Kanno commented: “During the first quarter of 2026, HeartCore continued to advance its strategic focus on financial services and capital markets-related services, with Go IPO remaining the key contributor for coming quarters....

VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”, “we” or “us”) (TSX: CFF) today reported results for the first quarter ended March 31, 2026.  EBITDA* was negative $7.7 million for the quarter compared to EBITDA of negative $12.6 million in the fourth quarter of 2025 and positive EBITDA of $4.9 million in the first quarter of 2025. Net loss was $9.4 million or ($0.23) per share for the quarter versus a net loss of $11.4 million or ($0.28) per share in the previous quarter and net income of $0.6 million or $0.02 per share in the first quarter of 2025. Selected Financial Highlights The following table summarizes our selected financial information for the comparative periods. The financial information reflects results of operations from our Mackenzie sawmill and power plant.Selected Financial...

 Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint. On track to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026. Ended the first quarter 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform,...

Company Advances Portfolio Streamlining Strategy, Including Proposed Sale of CMD in Potential $65 Million All-Cash Transaction Operating Expenses from Continuing Operations Declined Approximately 53%; Loss from Operations Improved Approximately 44%; Achieved Positive Cash Flow From Operations NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — 1847 Holdings LLC (OTC: LBRA) (“1847 Holdings” or the “Company”), a diversified acquisition holding company focused on identifying and monetizing overlooked, deep-value businesses, today announced financial results for the first quarter ended March 31, 2026. During the first quarter of 2026, the Company’s Board of Directors approved a plan to actively market for sale of CMD Inc. (“CMD”), which comprises the CMD segment within the Company’s Construction operations. As a result, CMD has been classified...

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026. “We continue to make meaningful progress advancing the belapectin program and further analyzing the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension. The additional analyses, including biomarker data, continue to support the potential of belapectin to impact disease progression in this high-risk population. We are looking forward to our upcoming data presentations at EASL later this month and our in-person Type-C meeting with FDA this quarter. Additionally, we remain focused on engaging with potential partners and leading experts to help determine...